熱門減肥藥物或可降低乳癌風險
Popular Weight-Loss Drugs May Reduce Breast Cancer Risk
Updated at: June 7, 2026 at 08:45 AM
在2026年美國臨床腫瘤學會(American Society of Clinical Oncology)年會上發表的一項最新研究，引發了對於熱門減肥藥物與乳癌預防之間潛在關聯的熱烈討論。
Recent research presented at the 2026 American Society of Clinical Oncology Annual Meeting has sparked excitement regarding a potential link between popular weight-loss drugs and breast cancer prevention.
類昇糖素胜肽-1(GLP-1)受體致效劑，例如Ozempic和Wegovy，常用於肥胖管理，但一項針對超過11萬名45至80歲女性的研究顯示，它們可能提供額外的健康益處。
GLP-1 receptor agonists, such as Ozempic and Wegovy, are commonly used for obesity management, but a study of over 110,000 women aged 45-80 suggests they might offer additional health benefits.
研究結果指出，開立這些藥物的女性，被診斷出罹患乳癌的機率約降低了30%。
Findings indicate that women prescribed these medications were approximately 30% less likely to be diagnosed with breast cancer.
持續的減重有助於降低脂肪組織中的雌激素生成，而這些藥物減輕全身性發炎以及改善胰島素阻抗的能力，也可能阻礙癌細胞的生長。
Sustained weight loss helps lower estrogen production in adipose tissue, while the drugs' ability to reduce systemic inflammation and improve insulin resistance may hinder cancer cell growth.
然而，專家呼籲應保持謹慎。
However, experts urge caution.
此外，某些癌症治療方法可能與減肥藥物產生衝突。
Furthermore, some treatments for cancer might conflict with weight-loss medications.
一如既往，有關個人健康決策，請務必諮詢您的醫生。
As always, consult your doctor regarding personal health decisions.
